Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Balance Sheets

v3.25.0.1
Consolidated Balance Sheets - USD ($)
Nov. 30, 2024
Nov. 30, 2023
Current Assets    
Cash and cash equivalents $ 560,960 $ 406,067
Marketable securities 2,935,183 574,183
Accounts receivable (net of allowance for doubtful accounts of $4,266,405 and $3,822,300, respectively) 7,309,094 6,576,240
Prepaid expenses 637,055 615,407
Inventory, current portion 657,703 768,877
Swap contract 0 122,113
Other current assets 454,598 389,950
Total current assets 12,554,593 9,452,837
Property and Equipment-net 21,894,263 20,996,883
Other Assets    
Intangible assets, net 921,254 989,121
Inventory, net of current portion 4,942,115 5,260,119
Goodwill 1,941,411 1,941,411
Deferred tax assets 20,802,023 20,492,749
Operating lease right-of-use asset 806,339 1,033,157
Deposits and other assets, net 815,635 746,493
Total other assets 30,228,777 30,771,050
Total assets 64,677,633 61,220,770
Current Liabilities    
Accounts payable 1,882,274 3,174,584
Accrued expenses 5,809,872 5,170,809
Note payable 170,488 165,641
Line of credit 3,520,000 1,222,728
Current portion of operating lease liability 428,334 225,686
Duke license agreement liability 0 1,200,000
Deferred revenue 9,788,574 9,704,553
Total current liabilities 21,599,542 20,864,001
Other Liabilities    
Deferred revenue, net of current portion 46,556,990 41,186,800
Contingent consideration 47,020 44,226
Note payable, net of current portion and debt issuance costs 8,310,045 8,430,037
Operating lease long-term liability 505,053 851,938
Long-term liability - revenue sharing agreements 875,000 875,000
Total other liabilities 56,294,108 51,388,001
Total liabilities 77,893,650 72,252,002
Commitments and contingencies (Note 12) 0 0
Stockholders' Deficit    
Preferred stock 0 0
Common stock ($.01 par value, 20,000,000 authorized; 14,869,619 issued and 8,082,159 outstanding as of November 30, 2024 and 14,849,246 issued and 8,286,785 outstanding as of November 30, 2023) 148,696 148,492
Additional paid-in capital 44,268,469 43,411,143
Treasury stock, at cost (24,855,556) (23,431,685)
Accumulated deficit (32,777,626) (31,159,182)
Total stockholders' deficit (13,216,017) (11,031,232)
Total liabilities and stockholders' deficit 64,677,633 61,220,770
Series A Junior Participating Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock 0 0
Tianhe Stem Cell Biotechnologies Inc [Member]    
Other Assets    
Investment $ 0 $ 308,000